Anti-Hypertensive Drugs - United States

United States

The Anti-Hypertensive Drugs market in the United States is forecasted to reach a revenue of €11.40bn in 2024.
It is anticipated that the market will experience an annual growth rate (CAGR 2024-2029) of -0.28%, leading to a market volume of €11.24bn by 2029.
Among all countries worldwide, United States is expected to generate the highest revenue, with €11.40bn in 2024.
The United States is experiencing a growing demand for innovative anti-hypertensive drugs due to the increasing prevalence of hypertension in the population.

Key regions: Japan, India, Italy, Brazil, South Korea

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Hypertensive Drugs market in United States has been experiencing significant growth over the past few years.

Customer preferences: One of the key drivers of this growth is the increasing prevalence of hypertension in the United States. With more and more people being diagnosed with high blood pressure, there is a growing demand for effective anti-hypertensive drugs. Additionally, there is a trend towards the use of combination therapies, which has led to an increase in the number of fixed-dose combination products available in the market.

Trends in the market: Another trend in the market is the increasing use of generic drugs. As patents for many of the leading anti-hypertensive drugs have expired, there has been a surge in the availability of generic versions of these drugs. This has led to increased competition and lower prices for consumers. Additionally, there has been a growing interest in the development of novel drugs that target specific mechanisms involved in hypertension.

Local special circumstances: The United States has a unique healthcare system, which has a significant impact on the anti-hypertensive drugs market. The high cost of healthcare in the United States means that many patients are unable to afford expensive brand-name drugs. This has led to a greater reliance on generic drugs and a focus on cost-effectiveness in the development of new drugs.

Underlying macroeconomic factors: There are a number of macroeconomic factors that are driving the growth of the anti-hypertensive drugs market in the United States. These include an aging population, increasing rates of obesity and diabetes, and a growing awareness of the importance of early intervention in the treatment of hypertension. Additionally, there has been a shift towards value-based care, which has led to greater emphasis on preventive care and the use of medications to manage chronic conditions like hypertension.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.